Skip to content


Online 16.9.2021

China Health tech series III – China NMPA registration of medical devices, IVDS, and medical software

Attendance to the webinar is free of charge, however, requires a registration via the link abowe.

Webinar participants will receive a link to join the event by e-mail one day prior to the event. The platform is MS Teams.

registration by September 16, 2021

Further information

Ms. Sanorita Li
Senior Advisor, Healthcare and Innovation, Business Finland China (EEST +5 hrs) (at)
tel: +86 18 600 599 682

Ms. Päivi Mähönen
Manager, Delegations
paivi.mahonen (at)
+358 40 343 3468

The Chinese medical device industry is large and has good potential.

In 2019, the industry was worth RMB 629 billion doubling its size in 2015. In 2020, due to strong demand for Covid-19 related medical devices, the industry’s value went up to RMB 800 billion. Overall, China’s medical device industry has been growing at a rate of 20% since 2015 and it now accounts for about 20% of the global medical device market share. Therefore it is a crucial market for Finnish health tech companies to consider.

Business Finland China together with Smart Life Finland program invite Finnish health tech companies interested in China to participate in the event on Thursday, September 16, 2021 at 10:00 - 11:30 (Finnish time). The overall purpose of the event is to introduce by China regulatory experts from Cisema the new top-level law for medical device regulation in China, the key regulatory hurdles including local testing requirements, clinical pathways and timelines, and differences between domestic and imported products. Other topics such as post-market surveillance and NMPA legal agent will also be presented together with specific product considerations for IVDs and software products, and relevant case studies.

This event is a part of Business Finland event series that started with Finland-China Joint Innovation Calls 2021 Launch in June 2021

Who should attend

Finnish health tech companies with interests in China.
Please note that the webinar is in English.

preliminary program